COMPPARE Newsletter: Summer 2024

connection


Dr. Nancy Mendenhall

A Message from Dr. Nancy Mendenhall

Over the past two years, we have been searching for funding opportunities to support another 5 years of follow-up for the COMPPARE cohorts to provide all participants with a minimum of 8 years of follow-up. This spring a new funding opportunity was announced by PCORI and the COMPPARE study has been invited to apply for this grant which would support another five years of follow-up and improve our understanding of long-term patient-centered outcomes. Read Dr. Mendenhall’s message.

 

 

 


Jack and Sheryl Morris Cancer CenterPartner Site Spotlight: The Rutgers Cancer Institute of NJ

In an area that ranks among the highest in the nation for cancer incidence, it is fortunate that more than 100,000 patients each year are served by the Rutgers Cancer Institute of New Jersey (CINJ), the only NCI-designated cancer center in the state and one recognized in U.S. News and World Report’s Best Hospital rankings. Follow the conversation here.

 

 


Bob Marckini and daughter Deb Hickey.Bob Marckini’s Extraordinary Life after Prostate Cancer

Marckini, a professional engineer, is a graduate of the MIT Greater Boston Executive Program and experienced in the photographic chemical, pharmaceutical, and specialty chemical industries. He is also a former SVP for a Fortune 500 company. What may be most remarkable about him, however, is what he has managed to accomplish after his prostate cancer treatment 24 years ago.  Read more about Bob’s journey.

 

 


PCORI

COMPPARE Poster Abstract to be Featured at the 2024 PCORI Annual Meeting

A COMPPARE poster abstract has been accepted by the Patient-centered Outcomes Research Institute (PCORI) and will be presented at its 2024 Annual Meeting, which will take place in Washington, D.C., October 22–23 – learn more.

 

 


U.S. County-Level Study Shows Life-Saving Impact of PSA Screening

U.S. Study Shows Life-Saving Impact of PSA Screening

A new study of U.S. counties found that higher rates of prostate-specific antigen (PSA) screening are linked to lower incidences of advanced or metastatic prostate cancer and reduced prostate cancer mortality rates in subsequent years – read more about this important research.

 

 


Research reported in this newsletter was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (PCS-2017C1-0422). The views, statements, and opinions presented in this newsletter are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its Board of Governors, or Methodology Committee.


Archive

We look forward to sharing our patient-centric news with you. Below you can find an archive of our issues and subscribe to receive COMPPARE Connection in your inbox.

 


COMPPARE Newsletter Subscription